Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | GCK | P35557 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | KLK7 | P49862 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | USP19 | O94966 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9102246 | 0.86 | KDM4E (0.39) | POLBEPHX2 | |
| SCHEMBL9107495 | 0.85 | PDE5A (0.45) | NPC1RAB9ANAMPTGCKKMT2A | |
| SCHEMBL9107932 | 0.83 | CNR2 (0.39) | NAMPTGCKNOTUMPTGDR2 | |
| SCHEMBL9106355 | 0.83 | NAMPT (0.37) | NPC1RAB9ANAMPTPTGDR2KMT2A | |
| SCHEMBL9106440 | 0.82 | PARK7 (0.43) | NPC1RAB9ANAMPTGCKHSD17B10 | |
| SCHEMBL9101677 | 0.81 | GCK (0.53) | NPC1RAB9AGCK | |
| SCHEMBL9908091 | 0.81 | GCK (0.53) | GCKPOLB | |
| SCHEMBL9104839 | 0.81 | GCK (0.53) | GCKPOLB | |
| SCHEMBL9104882 | 0.81 | GCK (0.53) | NPC1RAB9AGCKKMT2A | |
| SCHEMBL9103481 | 0.81 | NOTUM (0.40) | HSD17B10NOTUMKMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142705-A1 | ISATIN AND OXINDOLE COMPOUNDS | KESTER ROBERT FRANCIS (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142705-A1 | ISATIN AND OXINDOLE COMPOUNDS | GPR119, INSR, OAT | NPC1 2165/4885RAB9A 1778/4885NAMPT 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.